...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Carbonic anhydrase inhibitors: Design, synthesis and structural characterization of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms
【24h】

Carbonic anhydrase inhibitors: Design, synthesis and structural characterization of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms

机译:碳酸酐酶抑制剂:针对可药物治疗的人碳酸酐酶同工型的新型杂芳基-N-羰基苯磺酰胺的设计,合成和结构表征

获取原文
获取原文并翻译 | 示例

摘要

A set of heteroaryl-N-carbonylbenzenesulfonamides has been designed, synthesized, and screened as inhibitors of human carbonic anhydrases (hCAs). The new sulfonamide derivatives were tested against hCA I, hCA II, hCA VII, hCA IX, and hCA XII isoforms using acetazolamide (AAZ, 1) and topiramate (TPM, 2) as reference compounds. Six compounds were low nanomolar inhibitors of tumor-associated hCA IX isoform (K-i values < 10 nM); among them we identified three arylsulfonamides showing unexpected inefficacy over brain distributed hCA VII isoform (hCA IX/hCA VII selectivity ratio > 1500 for compound 5c). Thus, these compounds can offer the opportunity to highlight the interactions preventing the inhibition of hCA VII mainly expressed in central nervous system. Thereby, we used structural and computational techniques to study in depth the interaction with hCAs. In an effort to confirm the inhibitory action we determined crystal structures of five selected heteroaryl-N-carbonylbenzenesulfonamides (4a, 4b, 4e, 5c, and 5e) in complex with hCA II. Moreover, to explore the lack of inhibitory effects of selected compounds (e.g. 4b and Sc) we also performed docking studies into hCA VII catalytic site. (C) 2015 Elsevier Masson SAS. All rights reserved.
机译:已经设计,合成和筛选了一组杂芳基-N-羰基苯磺酰胺作为人碳酸酐酶(hCA)的抑制剂。使用乙酰唑胺(AAZ,1)和托吡酯(TPM,2)作为参考化合物,针对hCA I,hCA II,hCA VII,hCA IX和hCA XII同工型测试了新的磺酰胺衍生物。六种化合物是与肿瘤相关的hCA IX同工型的低纳摩尔抑制剂(K-i值<10 nM);在其中,我们鉴定了三种芳基磺酰胺类药物,它们在大脑分布的hCA VII亚型中表现出意想不到的功效(化合物5c的hCA IX / hCA VII选择性比> 1500)。因此,这些化合物可以提供机会来强调相互作用,从而阻止主要在中枢神经系统表达的hCA VII的抑制。因此,我们使用了结构和计算技术来深入研究与hCA的相互作用。为了确定抑制作用,我们确定了与hCA II配合的五种选定的杂芳基-N-羰基苯磺酰胺(4a,4b,4e,5c和5e)的晶体结构。此外,为了探索所选化合物(例如4b和Sc)缺乏抑制作用,我们还进行了对hCA VII催化位点的对接研究。 (C)2015 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号